Coherus, Junshi: Positive Final Overall Survival Results of Phase 3 in Nasopharyngeal Carcinoma

  Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status–

– Treatment resulted in a 37% reduction in the risk of death versus chemotherapy alone –

-– LOQTORZI is the first and only FDA-approved treatment for recurrent or metastatic NPC in all lines of therapy and will be available to NPC patients in the U.S. in January 2024 –

https://www.globenewswire.com/news-release/2023/11/28/2787206/33333/en/Coherus-and-Junshi-Biosciences-Announce-Publication-of-Positive-Final-Overall-Survival-Results-of-JUPITER-02-a-Phase-3-Trial-Evaluating-LOQTORZI-toripalimab-tpzi-as-Treatment-for-N.html